Foxglove (Digitalis purpurea)

Foxglove (Digitalis purpurea) contains cardiac glycosides including digoxin that strengthen heart muscle contractions by inhibiting sodium-potassium ATPase pumps. The raw plant is extremely toxic and only pharmaceutical preparations of isolated compounds are used medically.

Origin & History

Foxglove (Digitalis purpurea) is a biennial herbaceous plant native to western Europe, belonging to the Scrophulariaceae family, with leaves serving as the primary source for medicinal extracts. Extracts are typically obtained from dried leaves using methanolic or other solvent methods, yielding cardiac glycosides including digitoxin and related compounds as the main chemical constituents.

Historical & Cultural Context

Foxglove has been used in European traditional medicine since at least 1785, when William Withering documented its use for "dropsy" (edema from heart failure) and cardiac conditions. Traditionally applied as leaf infusions or powders to strengthen heart contraction and regulate rhythm, its use has declined in modern times due to toxicity concerns and the availability of purified alternatives.

Health Benefits

• Heart failure support: Purified derivatives like digoxin from foxglove have shown benefit in chronic heart failure patients with S3 gallop (evidence from double-blind trials, though specific to purified compounds, not raw herb)
• Cardiac rhythm regulation: Traditional use since 1785 for strengthening heart contraction and regulating rhythm, though modern use limited to purified forms due to toxicity concerns
• Potential anticancer activity: In vitro studies show cytotoxic activity of leaf extracts against cancer cell lines (IC50 0.78-15 μg/mL), particularly renal adenocarcinoma, but no human trials exist
• Edema reduction: Historically used for "dropsy" (edema from heart failure) as documented by William Withering in 1785, though no modern clinical trials on raw herb
• Enhanced cardiac contractility: Cardiac glycosides inhibit Na+/K+-ATPase, increasing intracellular calcium to enhance heart muscle contraction (mechanism established for purified compounds)

How It Works

Foxglove's cardiac glycosides (digoxin, digitoxin) bind to and inhibit Na+/K+-ATPase pumps in cardiac cell membranes, increasing intracellular sodium levels. This leads to increased intracellular calcium through the sodium-calcium exchanger, resulting in stronger myocardial contractions (positive inotropy). The compounds also slow electrical conduction through the AV node, reducing heart rate.

Scientific Research

Search results lack human clinical trials, RCTs, or meta-analyses specifically on Digitalis purpurea herb or extracts; evidence focuses on purified derivatives like digoxin. Two double-blind, placebo-controlled trials on digoxin (not raw herb) showed successful withdrawal in elderly patients with stable congestive heart failure and benefit in chronic heart failure patients with S3 gallop (sample sizes not specified in abstracts). No PubMed PMIDs for herb-specific RCTs were found.

Clinical Summary

Purified digoxin from foxglove has demonstrated efficacy in heart failure patients in multiple randomized controlled trials, including the DIG trial with 6,800 participants showing reduced hospitalizations. Studies specifically examined patients with systolic heart failure and S3 gallop sounds. However, clinical evidence applies only to pharmaceutical-grade isolated compounds, not whole plant preparations. The raw herb lacks standardization and poses significant toxicity risks.

Nutritional Profile

Foxglove (Digitalis purpurea) is not a nutritional food source and contains no meaningful macronutrient profile for dietary purposes. Its significance lies entirely in its bioactive secondary metabolites. Cardenolide cardiac glycosides are the primary compounds: digoxin (0.1–0.3% dry weight of leaves), digitoxin (0.2–0.4% dry weight), and gitoxin (trace to 0.1% dry weight). Digoxin concentration varies significantly by plant part — mature second-year leaves harvested before flowering contain the highest glycoside concentrations. Lanatoside C (a precursor glycoside) is present at approximately 0.1–0.2% dry weight. Secondary bioactives include digitalinum verum, gitaloxin, and odoroside. Flavonoids including luteolin and apigenin glycosides are present at low concentrations (estimated 0.5–1% dry weight total). Anthraquinones are absent. Saponins occur at trace levels. Mineral content includes potassium, calcium, and magnesium in amounts typical of leafy plants but nutritionally irrelevant given toxicity constraints. Crude fiber is present as with most leaves (~15–20% dry weight) but not bioavailable for human dietary use. Protein content is approximately 10–15% dry weight, again irrelevant due to toxicity. Bioavailability note: cardiac glycosides are highly bioavailable orally (digoxin ~70–80% absorption), which underpins both therapeutic utility and extreme toxicity risk — the therapeutic index is dangerously narrow with toxic dose only marginally above therapeutic dose.

Preparation & Dosage

No clinically studied dosage ranges for Digitalis purpurea herb, powder, or standardized extracts exist in human trials. Herb forms like powder are noted to be 300 times less potent than purified digoxin. Due to high toxicity risk and lack of standardized dosing data, self-use should be avoided. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Hawthorn, Motherwort, Lemon Balm, Magnesium, CoQ10

Safety & Interactions

Raw foxglove is extremely poisonous, with as little as 5 grams potentially fatal due to cardiac glycoside content. Symptoms include nausea, vomiting, irregular heartbeat, and cardiac arrest. Pharmaceutical digoxin interacts with numerous medications including diuretics, calcium channel blockers, and quinidine, requiring careful monitoring. Contraindicated in pregnancy and ventricular tachycardia, with narrow therapeutic window requiring regular blood level monitoring.